A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on the Single-Dose Pharmacokinetics of Sitravatinib
Latest Information Update: 25 Oct 2023
At a glance
- Drugs Sitravatinib (Primary)
- Indications Cancer; Gastric cancer; Liposarcoma; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Mirati Therapeutics
- 19 Oct 2023 Status changed from active, no longer recruiting to completed.
- 17 Nov 2022 Planned End Date changed from 1 Nov 2022 to 13 Apr 2023.
- 24 Aug 2022 Status changed from recruiting to active, no longer recruiting.